Abstract 167P
Background
Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer and is accompanied by frequent primary or acquired resistance to first-line treatment of chemo-immunotherapy resulting in very modest clinical benefit. Lurbinectedin is FDA-approved as a second-line treatment for SCLC.
Methods
In this study, we evaluated the effect of lurbinectedin on the immune microenvironment in SCLC in multiple immunocompetent mouse models and performed multi-color flow cytometry and bulk RNA sequencing.
Results
In multiple immunocompetent SCLC mouse models, lurbinectedin treatment remarkably enhanced the anti-tumor effect of PD-L1 blockade in tumors that show primary resistance to immunotherapy. Moreover, lurbinectedin caused significant tumor regression in mice that had developed acquired resistance to chemoimmunotherapy treatment demonstrating its efficacy as a superior second-line treatment. Lurbinectedin treatment caused micronuclei formation and activated the cGAS/STING pathway, induced the expression of Type I and II interferon pathways, and caused significant tumor infiltration of cytotoxic and memory/effector T-cells. Similarly, pro-inflammatory M1 type macrophages and dendritic cells were increased, while immunosuppressive M2 type macrophages and MDSC cells were dramatically decreased. Interestingly, lurbinectedin also led to significant induction of MHC class I in SCLC in vitro and in vivo models. Analysis of pre-and post-treatment clinical samples in patients with relapsed SCLCs validated the induction of MHC class I and interferon pathway genes. Finally, pre-and post-lurbinectedin treatment demonstrated a STING-mediated increase in damage-associated molecular patterns (DAMPs) associated with immunogenic cell death.
Conclusions
We provide the first mechanistic insight into the lurbinectedin-induced cGAS-STING activation and multimodal immune modulation in SCLC. Lurbinectedin is already approved as a second-line agent in SCLC. Hence, our findings highlight lurbinectedin as a potentially transformative therapy for SCLCs that have relapsed from chemoimmunotherapy treatment, paving the way for combination clinical trials with anti-PD-L1.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
126P - Evaluation of Myeloid Targeting Agents, PY159 and PY314, in Two Dose Expansion Phase 1b Trials in Platinum-Resistant Ovarian Cancer
Presenter: Oladapo Yeku
Session: Poster Display
116TiP - Randomized, open-label, phase II study of botensilimab (BOT) alone and in combination with balstilimab (BAL) versus standard-of-care in patients with refractory metastatic colorectal cancer
Presenter: Eric Van Cutsem
Session: Poster Display
127P - REGN5668 (MUC16xCD28 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase 1 dose-escalation study
Presenter: Ira Winer
Session: Poster Display
128P - A phase I dose escalation and expansion trial of LYT-200, a Galectin-9 antibody +/- tislelizumab
Presenter: Gerald Falchook
Session: Poster Display
129P - Naxitamab efficacy in patients with refractory/relapsed high-risk neuroblastoma and bone metastases as assessed by Curie score
Presenter: Brian Kushner
Session: Poster Display
131P - Safety and clinical efficacy of Roginolisib (IOA-244), the first oral allosteric modulator of phosphoinositide 3-kinase inhibitor delta (PI3K_)
Presenter: Anna Di Giacomo
Session: Poster Display
132P - A phase I clinical trial of QLS31905 in advanced solid tumors
Presenter: Yakun Wang
Session: Poster Display
133P - Phase 1/2 study of XTX101, a masked, tumor-activated Fc-enhanced anti-CTLA-4, in patients with advanced solid tumors
Presenter: Diwakar Davar
Session: Poster Display
134P - A Phase 1 Study Exploring the Safety and Tolerability of the Small Molecule PD-L1 Inhibitor INCB099318 in Select Advanced Solid Tumors
Presenter: David Pinato
Session: Poster Display
135P - Isunakinra as Monotherapy and Combined with Nivolumab for Treatment Resistant Advanced Solid Tumours: Exploratory Effect Data, Tolerability, and Pharmacokinetics from a Dose Escalation Trial
Presenter: Carlos Becerra
Session: Poster Display